Wuhan Hiteck Biological Pharma Co.,Ltd reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 680.74 million compared to CNY 608.2 million a year ago. Revenue was CNY 688.63 million compared to CNY 614.68 million a year ago.

Net loss was CNY 14.03 million compared to net income of CNY 27.65 million a year ago. Basic loss per share from continuing operations was CNY 0.11 compared to basic earnings per share from continuing operations of CNY 0.26 a year ago. Diluted loss per share from continuing operations was CNY 0.11 compared to diluted earnings per share from continuing operations of CNY 0.26 a year ago.